217 related articles for article (PubMed ID: 18380910)
1. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910
[TBL] [Abstract][Full Text] [Related]
2. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
3. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
4. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
[TBL] [Abstract][Full Text] [Related]
5. Medication persistence with weekly versus daily doses of orally administered bisphosphonates.
Ettinger MP; Gallagher R; MacCosbe PE
Endocr Pract; 2006; 12(5):522-8. PubMed ID: 17002926
[TBL] [Abstract][Full Text] [Related]
6. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
[TBL] [Abstract][Full Text] [Related]
8. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment].
Bartl R; Götte S; Hadji P; Hammerschmidt T
Dtsch Med Wochenschr; 2006 Jun; 131(22):1257-62. PubMed ID: 16755420
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Lee S; Glendenning P; Inderjeeth CA
Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
Cramer JA; Gold DT; Silverman SL; Lewiecki EM
Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
[TBL] [Abstract][Full Text] [Related]
11. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
13. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.
Recker RR; Gallagher R; MacCosbe PE
Mayo Clin Proc; 2005 Jul; 80(7):856-61. PubMed ID: 16007889
[TBL] [Abstract][Full Text] [Related]
14. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.
Cramer JA; Lynch NO; Gaudin AF; Walker M; Cowell W
Clin Ther; 2006 Oct; 28(10):1686-94. PubMed ID: 17157124
[TBL] [Abstract][Full Text] [Related]
15. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Gold DT; Safi W; Trinh H
Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
[TBL] [Abstract][Full Text] [Related]
16. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
Moro-Alvarez MJ; Díaz-Curiel M
Clin Interv Aging; 2008; 3(2):227-32. PubMed ID: 18686745
[TBL] [Abstract][Full Text] [Related]
17. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases.
Brankin E; Walker M; Lynch N; Aspray T; Lis Y; Cowell W
Curr Med Res Opin; 2006 Jul; 22(7):1249-56. PubMed ID: 16834823
[TBL] [Abstract][Full Text] [Related]
18. Differences in persistence among different weekly oral bisphosphonate medications.
Sheehy O; Kindundu CM; Barbeau M; LeLorier J
Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
[TBL] [Abstract][Full Text] [Related]
19. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Rietbrock S; Olson M; van Staa TP
QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
[TBL] [Abstract][Full Text] [Related]
20. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
